Connect announces Chinese collaborator submitted NDA for rademikibart

Connect Biopharma (CNTB) announced that the Company’s collaborator and exclusive licensee in China, Simcere Pharmaceutical, has submitted its New Drug Application, or NDA, for rademikibart to the National Medical Products Administration of China, or NMPA, for the treatment of atopic dermatitis, or AD, in adults and adolescents. In 2023, Connect and Simcere entered into an exclusive license and collaboration agreement for rademikibart in China. Under the agreement, Simcere was granted exclusive rights to develop, manufacture, and commercialize rademikibart for all indications in Greater China, including mainland China, Hong Kong, Macau, and Taiwan, while Connect retains rights in all other markets. As part of the agreement, Connect is eligible to receive milestone payments up to an aggregate remaining amount of approximately $110M upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.